8-K: Humana Faces Potential Headwinds from Preliminary Medicare Advantage Rate Changes

Humana anticipates a 1.6% negative impact on its benchmark funding due to proposed changes in Medicare Advantage payment rates, significantly worse than expected.

Summary

• The Centers for Medicare and Medicaid Services (CMS) released its preliminary 2025 Medicare Advantage and Part D payment rates, known as the Advance Notice, on January 31, 2024.
• CMS estimates that Medicare Advantage plans across the sector will experience an average decrease of 0.16% in benchmark funding.
• Humana's preliminary analysis indicates that the proposed changes would result in a 1.6% reduction in its benchmark funding, which is 160 basis points worse than their expectation of a flat rate environment.
• This negative impact is primarily due to proposed effective growth rate restatements and negative normalization factors, which Humana did not anticipate.
• Humana plans to provide actuarial data to CMS regarding its concerns and will continue to analyze the Advance Notice.
• Despite the preliminary negative impact, Humana maintains its 2025 outlook of $6 to $10 in Adjusted Earnings Per Share (EPS) growth.

Sentiment

Score: 4

Explanation: The document conveys a negative sentiment due to the worse-than-expected impact of the proposed Medicare Advantage payment rate changes, although the company maintains its EPS outlook. The negative impact is significant and could affect investor confidence.

Positives

• Humana is actively engaging with CMS to provide feedback on the proposed changes.
• The company maintains its 2025 outlook of $6 to $10 in Adjusted Earnings Per Share (EPS) growth.
• Humana will continue to analyze the Advance Notice and provide formal commentary.

Negatives

• The proposed changes in the Advance Notice are expected to negatively impact Humana's benchmark funding by 1.6%.
• This is significantly worse than the company's expectation of a flat rate environment.
• The negative impact is primarily due to proposed effective growth rate restatements and negative normalization factors.

Risks

• The final Medicare Advantage payment rates, to be published on April 1, 2024, could be more unfavorable than the preliminary rates.
• The proposed changes could negatively impact Humana's profitability and financial performance.
• There is uncertainty regarding the finalization of certain data related to fee-for-service county rebasing/re-pricing.

Future Outlook

Humana maintains its 2025 outlook of $6 to $10 in Adjusted Earnings Per Share (EPS) growth, despite the preliminary negative impact of the Advance Notice. The company will continue to analyze the Advance Notice and provide formal commentary to CMS.

Management Comments

• The company anticipates the proposals in the Advance Notice would result in a change to its benchmark funding that is approximately 160 basis points worse than its expectation of a flat rate environment.
• The company will provide actuarial data with respect to its concerns regarding these items.
• The company will continue to analyze the Advance Notice and will draw upon its program expertise to provide CMS formal commentary.

Industry Context

The announcement highlights the broader industry impact of the proposed changes to Medicare Advantage payment rates, with CMS estimating an average decrease of 0.16% in benchmark funding across the sector. Humana's specific situation is more challenging, indicating potential variability in the impact on different players in the industry.

Comparison to Industry Standards

• CMS estimates a 0.16% average decrease in benchmark funding for Medicare Advantage plans across the sector.
• Humana's anticipated 1.6% negative impact is significantly worse than the industry average, suggesting that Humana may be disproportionately affected by the proposed changes.
• Other major players in the Medicare Advantage space, such as UnitedHealth Group and CVS Health, will also be impacted by the CMS changes, but the specific impact on each company will vary based on their plan mix and geographic footprint.

Stakeholder Impact

• Shareholders may react negatively to the news of a worse-than-expected impact on benchmark funding.
• Medicare beneficiaries could potentially be affected by changes in the quality of care, affordability, and service provided by Humana.
• Employees may be concerned about the potential impact on the company's financial performance.

Next Steps

• Humana will provide actuarial data to CMS regarding its concerns.
• Humana will continue to analyze the Advance Notice.
• Humana will provide formal commentary to CMS on the impact of the Advance Notice.
• CMS will publish final Medicare Advantage payment rates on April 1, 2024.

Key Dates

Keywords

Medicare Advantage, CMS, payment rates, benchmark funding, Advance Notice, Humana, EPS, healthcare, actuarial data, normalization factors